TSXV:BTI.H - Post by User
Comment by
KayakerBCon Aug 13, 2022 12:20pm
128 Views
Post# 34893994
RE:RE:RE:RE:RE:RE:The recent Option Grant.
RE:RE:RE:RE:RE:RE:The recent Option Grant.Last week, you put up a lengthy post which prompted the usual unhelpful one-liner from BeenThere. To which you reasonably responded....
Make your case. Make an argument.
Make an argument, beenthere. Otherwise all you've got is mindless blah blah blah.
Now here is somebody (me) posting a contrary argument and your response is: "I can't be bothered arguing....".
Reduce (discount) that that by 2/3 for medical reasons and another 75% for clinical status reasons and you still get $22.5 million up front and almost $100 million in milestones. But those discounts are too big for the opportunity presented by xB3-001, in my opinion.
I'll make what I think is an easy prediction. If there is a XB3-001 deal, you will be highly critical of it.
I hope I'm dead wrong and there will be a big deal signed with big bucks up front that greases the move onto the NASDAQ with minimal dilution/pain for long term shareholders. But my expectation is that it will be underwhelming. As we've seen over and over, Pharmas are paying pocket change up front, I assume because XB3 has never been in a clinical trial. I don't see it being much different this time. I expect more cash up front because it's 001, but nothing like what you are expecting.
And if there will be an XB3-001 upfront payment anything remotely like what you expect, why is the current plan to pay for the upcoming Phase II study -- right before the NASDAQ listing -- with a financing? Why won't we have more than sufficient cash to fund it? (I expect both the Phase II and the listing to be delayed).
As it stands now, I'd still like to see what I said before. Try to sell the company for $2 US before we get diluted. I'll take that in a heart beat. And I'll hold my nose and still vote yes for $1 US.
I suspect you'll think I'm being very negative. I call it realistic. As I said, I hope I'm dead wrong and misjudging it. Won't be the first time I'm wrong. We'll see how it goes.